mavorixafor — Topline data
H1 2028
We expect to reach several key milestones in the near term, including completing enrollment in our Phase 3 4WARD trial this year and reporting topline results in the first half of 2028.Source filing
XFOR biotech catalysts & pipeline
X4 PHARMACEUTICALS INC · Data as of 2026-10-25
Upcoming catalysts
mavorixafor — Regulatory decision
Sep 2028–Apr 2029
Potential US FDA approval in late 2028/early 2029Source filing
mavorixafor — NDA/BLA submission
Late 2028
With a strengthened cash runway to the end of 2028, X4 is now expected to be able to complete the 4WARD trial, file a potential sNDA for the chronic neutropenia indication, and, if successful, launch mavorixafor in this new indication by the end of 2028.Source filing